Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
Introduction: The Challenge of Anticoagulation in an Aging Population
The management of atrial fibrillation (AF) in older adults presents one of the most significant paradoxes in contemporary clinical cardiology. While advanced age is a potent risk factor for thromboembolic stroke, it is simultaneously a primary driver of major bleeding complications associated with traditional anticoagulants. Current standard-of-care agents, specifically Direct Oral Anticoagulants (DOACs) like rivaroxaban, have significantly improved outcomes compared to vitamin K antagonists. However, the risk of intracranial and gastrointestinal hemorrhage remains a persistent barrier to optimal therapy, particularly in patients aged 75 and older who often present with frailty, renal impairment, and multiple comorbidities.
The Emergence of Factor XI Inhibition
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.